Rohto Pharmaceutical Co., Ltd.

As of March 31, 2026, Rohto Pharmaceutical Co., Ltd. carries a market capitalization of 544.01B, placing it among publicly traded companies globally. Its enterprise value stands at 535.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rohto Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Rohto Pharmaceutical Co., Ltd. has 225.96M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Rohto Pharmaceutical Co., Ltd. maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Rohto Pharmaceutical Co., Ltd.'s stock has gained approximately 14.84% over the past 52 weeks. The 50-day moving average sits at 2,862.95, while the 200-day moving average is 2,549.11.

As of March 31, 2026, Rohto Pharmaceutical Co., Ltd. holds 86.82B in cash and equivalents against 60.24B in total debt, resulting in a net debt position of -33.89B. Total book value stands at 301.83B, with working capital of 121.93B providing operational flexibility.

Rohto Pharmaceutical Co., Ltd.'s most recent stock split took place on December 29, 2022 with a 1:2 split ratio.